Negative Opinion on Lecanemab for Early Alzheimer’s Disease
Negative Opinion on Eisai’s Lecanemab for Early Alzheimer’s Disease An application for the marketing authorization of lecanemab, a promising treatment for early-stage Alzheimer’s disease, has faced a setback. The European […]